Skip to content
Back to meeting Original
Deborah Mukherji· @dmukherji · X·· 3 days agoScore45

JNJ-6143

Body

Exciting early data at #ESMO26 for JNJ-6143, a first-in-class oral AR-targeted RIPTAC in heavily pretreated #mCRPC @BGarmezy @OncoAlert

A promising new mechanism beyond conventional AR inhibition.

69 views · 6 likes · 5 reposts · 0 replies

Source: Deborah Mukherji · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.